Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.
Journal of Affective Disorders October 30, 2026 Andrew M Novick, Tiffany M Love, Rachel L Johnson et al.
Anhedonia is a core feature of major depressive disorder (MDD) that is frequently resistant to available treatments. Psilocybin's specific efficacy for anhedonia remains unclear. To evaluate psilocybin's efficacy for anhedonia in treatment-resistant MDD. In this randomized, double-blind, placebo-controlled trial, 20 participants with treatment-resistant MDD received psilocybin (25 mg or 1 mg)...
DOI: 10.1016/j.jad.2026.122676 (opens in new tab)
Full text (opens in new tab)
Psilocybin
Treatment-resistant depression
Anhedonia
Randomized controlled trial